Post hoc analysis evaluates Upa's efficacy in Crohn’s disease, indicating sustained benefits despite prior therapy.
Key Points
To assess the long-term efficacy of upadacitinib in patients with moderate-to-severe Crohn’s disease who had prior inadequate responses to biologic therapy.
Post hoc analysis of patients from the U-ENDURE LTE study
Patients continued treatment with upadacitinib for an additional 96 weeks after 52 weeks of maintenance
Efficacy assessed through clinical and endoscopic endpoints like remission and response